Sodium channel blockers for neuropathic pain

Expert Opinion on Therapeutic Patents

Volumn 20, Issue 6, 2010, Pages 755-779

  Zuliani, Valentina ^a   Rivara, Mirko ^a   Fantini, Marco ^a   Costantino, Gabriele ^a  

^a UNIVERSITY OF PARMA   (Italy)

Author keywords

Blockers; Neuropathic pain; Selectivity; Subtype; Voltage gated sodium channels

Indexed keywords

2 [4 (4 CHLORO 2 FLUOROPHENOXY)PHENYL]PYRIMIDINE 4 CARBOXAMIDE; A 803467; AMITRIPTYLINE; BENZENESULFONAMIDE DERIVATIVE; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; ESLICARBAZEPINE ACETATE; HARKOSERIDE; IMIDAZOLE DERIVATIVE; ISOXAZOLE DERIVATIVE; LAMOTRIGINE; LIDOCAINE; MEXILETINE; OXAZOLE DERIVATIVE; OXCARBAZEPINE; PHENYTOIN; PLACEBO; PYRAZINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRIMIDINONE DERIVATIVE; QUINAZOLINONE DERIVATIVE; RALFINAMIDE; SODIUM CHANNEL BLOCKING AGENT; TETRAHYDROISOQUINOLINE DERIVATIVE; THIAZOLE DERIVATIVE; TOPIRAMATE; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTICHOLINERGIC SYNDROME; ANTINOCICEPTION; ATAXIA; CHRONIC PAIN; CLINICAL TRIAL; CLUSTER HEADACHE; CONFUSION; DEPRESSION; DIABETIC NEUROPATHY; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; HUMAN; IC 50; MIGRAINE; NEUROPATHIC PAIN; POSTHERPETIC NEURALGIA; POSTOPERATIVE PAIN; REVIEW; SEDATION; SEIZURE; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; TRIGEMINUS NEURALGIA; UNSPECIFIED SIDE EFFECT; VISCERAL PAIN;

ANALGESICS; ANIMALS; CHRONIC DISEASE; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; NEURALGIA; PATENTS AS TOPIC; SODIUM CHANNEL BLOCKERS; SODIUM CHANNELS;

EID: 77952558790     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543771003774118     Document Type: Review

References (141)

1. Merskey H, Bogduk N. Classification of chronic pain: descriptions of chronic pain syndromes and definitions of pain terms. 2nd edition. IASP Press, Seattle; 1994
2. Catterall WA. A 3D view of sodium channels. Nature 2001;409:988-990
3. Bhattacharya A, Wickenden AD, Chaplan SR. Sodium channel blockers for the treatment of neuropathic pain. Neurotherapeutics 2009;6:663-678
4. Goldin AL, Barchi RL, Caldwell JH, et al. Nomenclature of voltage-gated sodium channels. Neuron 2000;28:365-368
5. Yu FH, Catteral W. The VGL-chanome: a protein superfamily specialized for electrical signalling and ionic homeostasis. Sci STKE 2004;2004(253):re 15
6. Yu FH, Westenbroek RE, Silos-Santiago I, et al. Sodium channel beta4, a new disulfide-linked auxiliary subunit with similarity to beta2. J Neurosci 2003;23:7577-7585
7. Raymond CK, Castle J, Garret-Engele P, et al. Expression of alternatively spliced sodium channel alpha-subunits genes: unique splicing patterns are observed in dorsal root ganglia. J Biol Chem 2004;279:46234-46241
8. Hains BC, Klein JP, Saab CY, et al. Upregulation of sodium channel Nav1.3 and functional involvement in neuronal hyperexcitability associated with central neuropathic pain after spinal cord injury. J Neurosci 2003; 23:8881-8892
9. Lai J, Hunter JC, Porreca F. The role of Voltage-Gated sodium channels in neuropathic pain. Curr Opin Neurobiol 2003;13:291-297
10. Nassar MA, Stirling CL, Forlani G, et al. Nociceptor-specific gene deletion reveals a major role for Nav1.7 (PN1) in acute and inflammatory pain. Proc Nat Acad Sci USA 2004;101:12706-12711
11. Yang Y, Wang Y, Li S, et al. Mutation in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia. J Med Genet 2004;41:171-174
12. Djouhry L, Fang X, Okuse K, et al. The TTX-resistant sodium channel Nav1.8 (SNS/PN3): expression and correlation with membrane properties in rat nociceptive primary afferent neurons. J Physiol 2003;550(Pt 3):739-752
13. Porreca F, Lai J, Bian D, et al. A comparison of the potential role of the tetrodotoxine-insensitive sodium channels, PN3/SNS and NaN/SNS2, in rat models of chronic pain. Proc Nat Acad Sci USA 1999;96:7640-7644
14. Lai J, Gold MS, Kim CS, et al. Inhibition of neuropathic pain by decreased expression of the tetrodotoxin-resistant sodium channel Nav1.8. Pain 2002;95:143-152
15. Khasaar SG, Gold MS, Levine JD. A tetrodotoxine-resistant sodium current mediated inflammatory pain in the rat. Neurosci Lett 1998;256:17-20
16. Dib-Hajj SD, Tyrrel R, Black JA, Waxman SG. NaN, a novel voltage gated Na channel, is expressed preferentially in peripheral sensory neurons and down-regulated after axotomy. Proc Nat Acad Sci USA 1998;95:8963-8968
17. Blum R, Kafitz KW, Konnert A. Neurotrophin-evoked depolarization requires the sodium channel Na(V)1.9. Nature 2002;419:687-693
18. Tarnawa I, B€olcskei H, Kocsis P. Blockers of voltage-gated sodium channel for the treatment of central nervous system diseases. Recent Patent CNS Drug Discov 2007;2:57-78
19. Hargus NJ, Patel MK. Voltage-gated Na+ channels in neurophatic pain. Expert Opinion Investig. Drugs 2007;16:635-645
20. Dickenson AH, Matthews EA, Suzuki R. Neurobiology of neuropathic pain: mode of action of anticonvulsants. Eur J Pain 2002;6:51-60
21. B€olcskei H, Tarnawa I, Kocsis P. Voltage-gated sodium channel blockers, 2001 -- 2006: an overview. Med Chem Res 2008;17:356-368
22. Wood JN, Boorman J. Voltage-gated sodium channel blockers; target validation and therapeutic potential. Curr Top Med Chem 2005;5:529-537
23. Baker MD, Wood JN. Involvement of Na+ channels in pain pathways. Trends Pharmacol Sci 2001;22:27-31
24. Amir R, Argoff CE, Bennett GJ. The role of sodium channels in chronic inflammatory and neuropathic pain. J Pain 2006;7:1-29
25. Loscher W, Schmidt D. New horizons in the development of antiepileptic drugs: the search for new targets. Epilepsy Res 2004;60:77-159
26. Meldrum BS, Rogawski MA. Molecular targets for antiepileptic drug development. Neurotherapeutics 2007;4:18-61
27. Ketelaars SOM, Gorter JA, van Vliet EA, et al. Sodium currents in isolated rat CA1 pyramidal and dentate granule neurones in the post-status epilepticus model of epilepsy. Neuroscience 2001;105:109-120
28. Ellerkmann RK, Remy S, Chen J, et al. Molecular and functional changes in voltage-dependent Na+ channels following pilocarpine-induced status epilepticus in rat dentate granule cells. Neuroscience 2003;119:323-333
29. Kahlig KM, Rhodes TH, Pusch M, et al. Plat divergent properties of NaV1.1 mutations associated with familial hemiplegic migraine. Biophys J 2008;94:1866
30. Saint DA. The cardiac persistent sodium current: an appealing therapeutic target? Br J Pharmacol 2008;153:1133-1142
31. Zaza A, Belardinelli L, Shryock JC. Pathophysiology and pharmacology of the cardiac "late sodium current". Pharm Ther 2008;119:326-339
32. Sakurai M, Kanazawa I. Positive symptoms in multiple sclerosis: their treatment with sodium channel blockers, lidocaine and mexiletine. J Neurol Sci 1999;162:162-168
33. Palop J, Thwin M, Ho K, et al. P1-078: alterations in voltage-gated sodium channels in transgenic mouse models of alzheimer's disease: implications for Abeta-induced network dysfunction. Alzheimer's Dementia 2008;4:T229
34. Oyama F, Miyazaki H, Sakamoto N, et al. Sodium channel beta4 subunit: down-regulation and possible involvement in neuritic degeneration in Huntington's disease transgenic mice. J Neurochem 2006;98:518-529
35. Meisler HM, Kearney JA. Sodium channel mutations in epilepsy and other neurological disorders. J Clin Invest 2005;115:2010-2017
36. Trudeau MM, Dalton JC, Day JW, et al. Heterozygosity for a protein truncation mutation of sodium channel SCN8A in a patient with cerebellar atrophy, ataxia, and mental retardation. J Med Genet 2006;43:527-530
37. Clare JJ, Tate SN, Nobbs M, Romanos MA. Voltage-gated sodium channels as therapeutic targets. Drug Discov Today 2000;5:506-520
38. Chahine M, Chatelier A, Babich O, Krupp JJ. Voltage-gated sodium channels in neurological disorders. CNS Neurol Disord Drug Targets 2008;7:144-158
39. Matulenko MA, Scanio MJC, Kort ME. Voltage-gated sodium channel blockers for the treatment of chronic pain. Curr Top Med Chem 2009;9:362-376
40. Zuliani V, Patel MK, Fantini M, Rivara M. Recent advances in the medicinal chemistry of sodium channel blockers and their therapeutic potential. Curr Top Med Chem 2009;9:396-415
41. Backonja MM. Use of anticonvulsants for treatment of neuropathic pain. Neurology 2002;59:S14-17
42. Backonja MM. Anticonvulsants (antineuropathics) for neuropathic pain syndromes. Clin J Pain 2000;16:S67-72
43. Tremont-Lukats IW, Megeff C, Backonja MM. Anticonvulsants for neuropathic pain syndromes: mechanism of action and place in therapy. Drugs 2000;60:1029-1052
44. Pappagallo M. Newer antiepileptic drugs: possibile uses in the treatment of neuropathic pain and migraine. Clin Ther 2003;25:2506-2538
45. Vestergaard K, Andersen G, Gottrup H, et al. Lamotrigine for central poststroke pain: a randomized controlled trial. Neurology 2001;56:184-190
46. Fitton A, Goa KL. Lamotrigine. An update of its pharmacology and therapeutic use in epilepsy. Drugs 1995;50:691-713
47. Titlic M, Jukic I, Tonkic A, et al. Lamotrigine in the treatment of pain syndromes and neuropathic pain. Bratisl Lek Listy 2008;109:421-424
48. Devulder J, De Laat M. Lamotrigine in the treatment of chronic refractory neuropathic pain. J Pain Symptom Manage 2000;19:398-403
49. Vinik AI, Tuchman M, Safirstein B, et al. Lamotrigine for treatment of pain associated with diabetic neuropathy: results of two randomised, double-blind, placebo controlled studies. J Pain 2006;128 (1-2):169-179
50. Fallace MS, Rowbotham M, Bennet GJ, et al. A multicenter, double-blind, randomized, placebo-controlled crossover evaluation of a short course of 4030W92 in patients with chronic neuropathic pain. J Pain 2002:3;227-233
51. Finnerup NB, Otto M, McQuay HJ, et al. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 2005;118:289-305
52. Campbell FG, Graham JG, Zilkha KJ. Clinical trial of carbamazepine (tegretol) in trigeminal neuralgia. J Neurol Neurosurg Psychiatry 1966;29:265-267
53. Rull JA, Quibrera R, Gonzalez-Millan H, Lozano Castaneda O. Symptomatic treatment of peripheral diabetic neuropathy with carbamazepine (tegretol): double blind crossover trial. Diabetologia 1969;5:215-218
54. Wilton TD. Tegretol in the treatment of diabetic neuropathy. S Afr Med J 1974;48:869-872
55. Shorvon S. Oxcarbazepine: a review. Seizure 2000;9:75-79
56. Ambrosio AF, Soares-Da-Silva P, Carvalho CM, Carvalho AP. Mechanism of action of carbamazepine and its derivatives, oxcarbazepine, BIA 2-093, and BIO 2-024. Neurochem Res 2002;27:121-130
57. Guay DR. Oxcarbazepine, topiramate, zonisamide, and levetiracetam: potential use in neuropathic pain. Am J Geriatr Pharmacother 2003;1:18-37
58. Dogra S.Beydoun S, Mazzola J, et al. Oxacarbazepine in painful diabetic neuropathy: a randomized, placebo controlled study. Eur J Pain 2005;9:543-554
59. Grosskopf J, Mazzola J, Wan Y, Hopwood M. A randomized, placebo-controlled study of oxacarbazepine in painful diabetic neuropathy. Acta Neurol Scand 2006;114:177-180
60. Portela & CA SA (Vieira Araujo Soares Da Silva PM). Use of 5H-dibenz[b,f] azepin-5-carboxamide derivatives in the treatment of neuropathic pain. WO094694; 2007
61. Chong MS, Libretto SE. The rational and use of topiramate for treating neuropathic pain. Clin J Pain 2003;19:59-68
62. Veneroni O, Maj R, Calabresi M, et al. Anti-allodynic effect of NW-1029, a novel Na+ channel blocker, in experimental animal models of inflammatory and neuropathic pain. Pain 2003;102:17-25
63. Colombo E, Curatolo L, Caccia C, et al. Ralfinamide acts through NMDA receptor complex: a central role for chronic pain treatment. Eur J Pain 2007;11:152-153
64. Zhang SH, Blech-Hermoni Y, Faravelli L, Seltzer Z. Ralfinamide administered orally before hindpaw neurectomy or postoperatively provided long-lasting suppression of spontaneous neuropathic pain-related behavior in the rat. Pain 2008;139:293-305
65. Fallace MJ. Update on pharmacotherapy guidelines for treatment of neuropathic pain. Curr Pain Headache Rep 2007;11:208-214
66. Kalso E, Tasmuth T, Neuvonen PJ. Amitriptyline effectively relieves neuropathic pain following treatment of breast cancer. Pain 1996;64:293-302
67. Errington AC, Stohr T, Heers C, Lees G. The investigational anticonvulsant Lacosamide selectively anhances slow inactivation of voltage-gated sodium channels. Mol Pharm 2008;73:157-169
68. Beyreuther BK, Callizot N, Stohr T. Antinociceptive efficacy of lacosamide in a rat model for painful diabetic neuropathy. Eur J Pharmacol 2006;539:64-70
69. Beyreuther BK, Callizot N, Brot MD, et al. Antinociceptive efficacy of lacosamide in rat models for tumor- and chemotherapy-induced cancer pain. Eur J Pharmacol 2007;565.98-104 (Pubitemid 46782774)
70. Carrol IR, Kaplan KM, Mackay SC. Mexiletine therapy for chronic pain: survival analysis identified factors predicting clinical success. J Pain Symptom Manage 2008;35:321-326
71. Mao J, Chen LL. Systemic lidocaine for neuropathic pain relief. Pain 2000;87:7-17
72. Jarvis MF, Honore P, Shieh CC, et al. A-803467, a potent and selective NaV1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat. Proc Natl Acad Sci USA 2007;104:8520-8525
73. McGaraughty S, Chu KL, Scanio MJ, et al. A selective NaV1.8 sodium channel blocker, A-803467, attenuates spinal neuronal activity in neuropathic rats. J Pharm Exp Ther 2008;324:1204-1211
74. Ilyin VI, Pomonis JD, Whiteside GT, et al. Pharmacology of 2-[4-(4-chloro-2-fluorophenoxy) phenyl]-pyrimidine-4-carboxamide: a potent, broad-spectrum state-dependent sodium channel blocker for treating pain states. J Pharmacol Exp Ther 2006;318:1083-1093
75. Ilyin VI, Hodges DD, Whittemore ER, et al. V102862 (Co 102862): a potent, broad-spectrum state-dependant blocker sodium channel blocker of mammalian voltage-gated sodium channels. Br J Pharmacol 2005;144:801-812
76. Merck and Co., Inc. Biaryl substituted 6-membered heterocycles as sodium channel blockers. WO084824; 2004
77. Merck and Co. Biaryl substituted triazoles as sodium channel blockers. WO083190; 2004
78. Merck and Co. Biaryl substituted triazoles as sodium channel blockers. WO083189; 2004
79. Merck and Co. Biaryl substituted pyrazoles as sodium channel blockers. WO092140; 2004
80. Merck and Co. Biaryl substituted thiazoles, oxazoles and imidazoles as sodium channel blockers. WO094395; 2004
81. Merck and Co. Substituted triazoles as sodium channel blockers. WO047270; 2005
82. Merck and Co. Biaryl substituted pyrazinones as sodium channel blockers. WO097136; 2005
83. Merck and Co. Substituted triazoles as sodium channel blockers. US0119261; 2005
84. Merck and Co. Substituted triazoles as sodium channel blockers. US0074890; 2005
85. Merck and Co. Biaryl substituted pyrazoles as sodium channel blockers. US0183785; 2006
86. Merck and Co. Biaryl substituted triazoles as sodium channel blockers. US0171777; 2008
87. Merck and Co. Biaryl substituted pyrazinones as sodium channel blockers. US0280873; 2008
88. Bear B, Asgian J, Termin A, Zimmerman N. Small molecules targeting sodium and calcium channels for neuropathic pain. Curr Opin Drug Discov Dev 2009;12:543-561
89. Pfizer Ltd. Pyrazine derivatives. WO052123; 2007
90. Pfizer Ltd. Pyridine derivatives as sodium channel modulators. WO083239; 2007
91. Pfizer Ltd. Pyridine derivatives. WO135826; 2008
92. Pfizer Ltd. Pyridine derivatives. US0048306; 2009
93. Glaxo Group Ltd. Pyridine derivatives as sodium channel modulators. WO017691; 2008
94. Glaxo Group Ltd. Novel compounds. US0058391; 2008
95. Glaxo Group Ltd. Preparation of (fluorobenziloxyphenyl)prolinamide as sodium channel modulators. WO042239; 2007
96. Glaxo Group Ltd. Novel compounds. US0280969; 2008
97. Glaxo Group Ltd. Prolinamide derivatives as sodium channel modulators. WO042250; 2007
98. Glaxo Group Ltd. Preparation of a-aminocarboxamides, especially phenylprolinamide and (pyridin-2-yl) prolinamide derivatives as sodium channel modulators. WO042240; 2007
99. University of Greenwich. New medical use of triazine derivatives. WO007149; 2008
100. University of Greenwich. Cyclic traiazo and diazo sodium channel blockers. WO090431; 2009
101. Astrazeneca AB. New Compounds 955. WO010784; 2009
102. Merck and Co. Benzazepinones as sodium channel blockers. WO145922; 2007
103. Chabal C, Russell LC, Burchiel KJ. The effect of intavenous lidocaine, tocainide, and mexiletine on spontaneously active fibers originating in rat sciatin neuromas. Pain 1989;38:333-338
104. Hoyt SB, London C, Gorin D, et al. Discovery of a novel class of benzazepinone hNav1.7 blockers: potential treatments for neuropathic pain. Bioorg Med Chem Lett 2007;17:4630-4634
105. Hoyt SB, London C, Ok H, et al. Benzazepinone NaV1.7 blockers: potential treatments for neuropathic pain. Bioorg Med Chem Lett 2007;17:6172-6177
106. Merck and Co. Benzazepinones as sodium channel blockers. US0181946; 2009
107. Chaplan SR, Bach FW, Pogrel JW, et al. Quantitative assessment of tactile allodynia in the rat paw. Neurosci Methods 1994;53:55-63
108. Merck and Co. Substituted benzodiazepinones, benzoxazepinones and benzothiazepinones as sodium channel blockers. WO106077; 2008
109. Xenon Pharmaceutical Inc. Quinazolinone and fused pyrimidinone compounds and their use in treating sodium channel-mediated diseases and conditions. WO094909; 2008
110. Xenon Pharmaceutical Inc. Pyridopyrimidinone compounds useful in treating sodium channel-mediated diseases or conditions. US0194616; 2008
111. Xenon Pharmaceutical Inc. Preparation of pyridopyrimidinone compounds useful in treating sodium channel-mediated diseases or conditions. WO097991; 2008
112. Xenon Pharmaceutical Inc. Methods of using bicyclic compounds in treating sodium channel-mediated diseases or conditions. WO134553; 2008
113. Xenon Pharmaceutical Inc. Methods of usinig benzodioxine compounds in treating sodium channel-mediated diseases or conditions. WO106633; 2008
114. Astrazeneca AB. Phenyl- 1,2,3,4-tetraidroisoquinolinone derivatives and their use in the treatment of pain disorder. WO005459; 2009
115. Astrazeneca AB. New compounds 805. WO130319; 2008
116. Xenon Pharmaceutical Inc. Spiro(furo [3,2-C]pyridine-3-3¢-indol)- 2¢(1¢H)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain. WO046049; 2008
117. Xenon Pharmaceutical Inc. Spiro-oxindole compounds and their preparation, pharmaceutical composition and use as sodium channel blockers. WO110917; 2006
118. Xenon Pharmaceutical Inc. Preparation of spiro-oxindole compounds as therapeutic agents. WO060789; 2008
119. Xenon Pharmaceutical Inc. Peparation of tricyclic spiro-oxindole derivatives use as therapeutic agents. WO046046; 2008
120. Xenon Pharmaceutical Inc. Peparation of spiro-heterocyclic derivatives use as therapeutic agents. WO046084; 2008
121. Astrazeneca Pharmaceutical LP. 3-oxoisondoline-1-carboxamide derivatives as analgesic agents. US0291983; 2009
122. Vertex Pharmaceutical Inc. Composition useful as inhibitors of voltage-gated sodium channels. US0238733; 2007
123. Vertex Pharmaceutical Inc. Ion channel modulators and methods of use. US0293737; 2008
124. Icagen, Inc. Inhibitors of ion channels. US056099; 2007
125. Icagen, Inc. Sodium channel inhibitors. WO012241; 2009
126. Icagen, Inc. Sodium channel inhibitors. WO023740; 2009
127. Vernalis (R&D) Ltd claimed. Antagonist of SNS sodium channel. WO007057; 2007
128. Vernalis (R&D) Ltd claimed. Azacyclic compounds as inhibitors of SNS sodium channels. WO007069; 2007
129. Xenon Pharmaceutical Inc. Methods of using thiazole, oxazole and imidazole compounds in treating sodium channel-mediated diseases or conditions. WO101029; 2008
130. Xenon Pharmaceutical Inc. Potent and Selective NaV 1.7 sodium channel blockers. WO109324; 2007
131. Xenon Pharmaceutical Inc. Methods of using piperazine compounds in treating sodium channel-mediated diseases or conditions. WO147864; 2008
132. Xenon Pharmaceutical Inc. Methods of using diazepinone compounds in treating sodium channel-mediated diseases or conditions. WO109856; 2008
133. Xenon Pharmaceutical Inc. Methods of using tricyclic compounds in treating sodium channel-mediated diseases or conditions. WO121859; 2008
134. Xenon Pharmaceutical Inc. Methods of using hydroxycyclohexane and hydroxypiperidine compounds in treating sodium channel-mediated diseases or conditions. US061625; 2008
135. Akada Y, Ogawa S, Amano K, et al. Potent analgesic effects of a putative sodium channel blocker M58373 on formalin-induced and neuropathic pain in rats. Eur J Pharmacol 2006;536:248-255
136. Xenon Pharmaceutical Inc. Methods of using quinolinone compounds in treating sodium channel-mediated diseases or conditions. WO113006; 2008
137. Shekhar C. Hitting a nerve: ion channels may hold the key for treating chronic pain. Chem Biol 2009;16:1-2
138. Huang CJ, Harootunian A, Maher MP, et al. Characterization of voltage-gated sodium channel blockers by electrical stimulation and fluorescence detection of membrane potential. Nat Biotechnol 2006;24:439-446
139. Schroeder K, Neagle B, Trezise DJ, Worley J. Ionworks HT: a new high-throughput electrophysiology measurement platform. J Biomol Screen 2003;8:50-64
140. Nau C, Wang GK. Interaction of local anestetich with voltage-gated Na+ channels. J Membr Biol 2004;201:1-8
141. Priest BT. Future potential and status of selective sodium channel blockers for the treatment of pain. Curr Opin Drug Discov Devel 2009;12:682-692